grant
Development of new antibody-fusion inhibitor conjugates to block HIV infection
Organization NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESLocation UNITED STATES
NIHUS FederalResearch GrantFY2025AIDSAIDS VirusAcquired Immune DeficiencyAcquired Immune Deficiency SyndromeAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency SyndromeAcquired Immunodeficiency Syndrome VirusAddressAffinityAnti-viral AgentsAnti-viral Drug ResistanceAnti-viral Drug ResistantAntibodiesBindingBiologicalC-C CKR-5C-C CKR-5 GeneC-C Chemokine Receptor Type 5C-C Chemokine Receptor Type 5 GeneCC Chemokine Receptor 5CC-CKR-5CC-CKR-5 GeneCC-CKR5CCCKR5CCCKR5 GeneCCR-5CCR-5 GeneCCR5CCR5 ProteinCCR5 ReceptorsCCR5 geneCD195 AntigenCD195 Antigen GeneCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCHEMR13CHEMR13 GeneCKR-5CKR-5 GeneCKR5CKR5 GeneCKR5 ReceptorsCMKBR5CMKBR5 GeneCXC-R4CXCR-4CXCR4CXCR4 geneCell surfaceChemokine (C-C Motif) Receptor 5Chemokine (C-C) Receptor 5Chemokine (C-C) Receptor 5 GeneClinical Treatment MoabCollectionD2S201EDevelopmentDoseDrugsFB22GenerationsGoalsHIVHIV Envelope Glycoprotein gp120HIV Envelope Protein gp120HIV InfectionsHIV env Protein gp120HIV-1 Fusion Co-ReceptorHIV-1 Fusion Co-Receptor GeneHM89HSY3RRHTLV-III InfectionsHTLV-III gp120HTLV-III-LAV InfectionsHuman Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsIndividualInfection preventionLAP3LAV-HTLV-IIILCR1LESTRLengthLinkLymphadenopathy-Associated VirusMammalian CellMedicalMedicationMembraneMethodsMolecular InteractionMonoclonal AntibodiesNPY3RNPYRNPYRLNPYY3RPathogenicityPeptidesPharmaceutical PreparationsPredispositionPrevent infectionProteinsReceptor ProteinRecombinantsRegimenReportingResearchRoleSchemeSiteSpecificitySusceptibilityT4 CellsT4 LymphocytesTherapeuticToxic effectToxicitiesTransmissionVHHVHH antibodyViralViral ActivityViral DiseasesViral Drug ResistanceViral FunctionViral Gene ProductsViral Gene ProteinsViral PhysiologyViral ProteinsVirusVirus DiseasesVirus InhibitorsVirus-HIVanti-viral compoundanti-viral drugsanti-viral efficacyanti-viral medicationanti-viral therapeuticanti-viralsbiologiccamelid antibodycamelid based antibodycamelid derived antibodycamelid derived fragmentcamelid heavy chain only Abscamelid immunoglobulincamelid single chain antibodycamelid variable heavy chaincell typechemical synthesisclinical applicabilityclinical applicationdevelopmentaldrug/agentgp120gp120 ENV Glycoproteingp120(HIV)improvedinhibitormAbsmembrane structuremonoclonal Absmutantnanobodiesnanobodynew approachesnovelnovel approachesnovel strategiesnovel strategypolypeptidereceptorresistance mechanismresistance to anti-viralresistant mechanismresistant to anti-viralsdAbside effectsingle domain antibodiessocial rolesynthetic peptidetherapeutic targettooltransmission processvariable heavy chain antibodyviral infectionviral infection mechanismviral inhibitorviral resistancevirus infectionvirus infection mechanismvirus proteinvirus resistancevirus-induced disease
Description preview
Substantial scientific effort has been expended to develop tools and therapies to prevent infection by and transmission of HIV. Although these efforts have provided an impressive collection of therapies that diminish the pathogenicity caused by HIV, many unaddressed challenges remain, as evidenced by the enduring medical and societal impact of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click